Objective To investigate the prognostic effects of neutrophil to lymphocyte ratio(NLR)on progression free survival(PFS)in patients with non-small cell lung cancer(NSCLC)receiving single-agent immunotherapy.Methods Retrospective analysis was made on 30 patients with NSCLC who received single-agent immunotherapy.NLR and platelet to lymphocyte ratio(PLR)before immunotherapy was collected,and Kaplan-Meier method was used for survival analysis to explore the factors affecting PFS.Results Patients were divided into high NLR group(n=15)and low NLR group(n=15)according to the median NLR of 3.30.Patients were divided into high PLR(n=15)and low PLR(n=15)groups based on a median PLR of 178.11,with a median PFS of 2.9 months for all patients.Kaplan-Meier survival analysis showed that the median PFS in the low NLR group was 3.9 months[95%CI=(2.006,5.794)],which was significantly longer than 2.8 months[95%CI=(2.552,3.048)]in the high NLR group,with a Log-rank test yielding P=0.002<0.05.The median PFS in the high PLR group was 2.7 months[95%CI=(2.416,2.984)],which was significantly shorter than 3.8 months[95%CI=(3.043,4.557)]in the low PLR group,with a Log-rank test yielding P=0.03<0.05.Univariate analysis showed that gender,NLR and PLR were the influencing factors of PFS(P<0.05).After checking gender factors by COX multiple regression model,the results of multivariate analysis showed that NLR was the influential factor for PFS in NSCLC patients receiving monotherapy(P=0.001<0.05).PLR was not an influential factor for PFS in NSCLC patients receiving single-agent immunotherapy(P>0.05).Conclusion In NSCLC patients receiving single-agent immunotherapy,the PFS of patients with lower levels of NLR is longer,which can predict the prognosis of NSCLC patients receiving immunomonotherapy.
关键词
中性粒细胞与淋巴细胞比值/血小板与淋巴细胞比值/非小细胞肺癌/单药免疫治疗/无进展生存期/预测价值
Key words
Neutrophil to lymphocyte ratio/Platelet to lymphocyte ratio/Non-small cell lung cancer/Single-agent immunotherapy/Progression-free survival/Predictive value
维普
万方数据